[12] Patent
[11] Patent No.:GC0009258  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/140758
Date of the Decision to Grant the Patent:03/Dec/2018

[21] Application No.:GC 2015-29898

[22] Filing Date:17/8/2015

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
20/8/2014
62/039,622

[72] Inventors:1- Hai-Yun Xiao،2- Alaric J Dyckman،3- Zili Xiao،4- Michael G. Yang،5- T.G. Murali Dhar،6- John L. Gilmore،7- David Marcoux

[73] Owner: BRISTOL-MYERS SQUIBB COMPANY, Route 206 and Province Line Rd. NJ 08543, Princeton, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: C07C 215/42, 217/52, 217/58, 219/24, 233/41, 233/65, 251/50, 251/52, 251/54, 271/34, 317/28, 317/32, 321/16, 321/22, 321/28; C07D 213/32, 213/69, 213/70, 215/12, 217/24, 231/12, 231/20, 239/26, 241/12, 277/24, 305/08, 309/06, 309/12, 311/58, 311/76, 319/20, 333/16; C07F 7/08, 9/117, 9/62, 9/6503, 9/6509, 9/655, 9/6553 (2006.01)

[56] Cited Documents:

-WO 2008/079382 A1 (ABBOTT LAB [US]; WALLACE GRIER A [US]; BREINLINGER ERIC C [US]; CUSACK) 03 July 2008  
Examiner: PH. Sultana K. AlOudah

[54] SUBSTITUTED BICYCLIC COMPOUNDS
[57] Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is OH or OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
No. of claims: 9


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.